## Contents

### Volume 83 Issue 2 | ARD February 2024

#### Editorial

F Berenbaum

#### Viewpoint

136 **Rheumatology and Long COVID: lessons from the study of fibromyalgia**  
D J Clause, L Calabrese

#### Review

139 **Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story**  

#### Rheumatoid arthritis

161 **Long-term mortality in treated-to-target RA and UA: results of the BeSt and IMPROVED cohort**  
S L Hecker, J M Maassen, S le Cessie, Y P M Coekop-Ruiteman, M Giller-Yaksell, W Lens, T W J Huizinga, S A Bergozen, C F Allaart

169 **Definition of rheumatoid arthritis flare based on SDAI and CDAI**  
V Kozlitz, A Kerschbaum, J S Smolen, E K Kristianslund, S A Proven, T K Kven, D Altekrue

177 **Abatacept and non-melanoma skin cancer in patients with rheumatoid arthritis: a comprehensive evaluation of randomised controlled trials and observational studies**  
T A Somer, I Dong, S Suisse, K Michael, S Pedro, M Hechberg, M Bowers, J Asking, T Frisell, A Strengfjeld, Y Meisner, V Khatchouk, A Domimques, M A Maldonado

### Psoriatic arthritis

194 **Specific descriptions of axial involvement are associated with radiographic damage development after 2 years in psoriatic arthritis patients**  
M de Hooge, A Ichenben, S Stauf, E A Nzeaussu, D E Llaatu, R Lories, F Van den Bosch, K De Vlaman

#### Spondyloarthritis

199 **Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE and BE MOBILE 2 studies**  
X Baraliakos, A Dethar, D van de Heijde, M Magrey, W P Maksymowych, T Tomita, H Xu, U Massow, C Fleurenck, A M Ellis, T Vaux, J Shephard-Smith, A Marten, L S Gensler

214 **Card9/neutrophil signalling axis promotes IL-17A-mediated ankylosing spondylitis**  
H L Rosenzweig, E E Vance, K Astre-Konadu, K V Konye, J L Lee, A A Dethar, R Sen, L Caplan, R J Napier

#### Vasculitis

223 **Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial**  
D Geetha, A Dua, H Yue, J Springer, C Satarakan, D Jayne, P Mok, ADVOCATE Study Group

233 **Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials**  

#### Early arthritis

181 **Rheu-VOR study: optimising healthcare of rheumatic diseases by multiprofessional coordinating centres**  

---

**More Contents ▶**

---

Disclaimer: The Editor of ARD has been granted editorial freedom and ARD is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. ARD is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by ARD does not imply endorsement. Neither BMJ nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from ARD (except for liability which cannot be legally excluded).

Copyright: © European Alliance of Associations for Rheumatology, EULAR 2024. Published by BMJ. All rights reserved. ARD is published by BMJ Publishing Group Ltd. typeset by Exeter Promedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to Annals of the Rheumatic Diseases, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.
Contents

Autoimmunity
242 Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotyping
H Tanaka, Y Okada, S Nakayamada, Y Miyazaki, K Sonehara, S Namba, S Honda, Y Shirai, K Yamamoto, K Kuro, M Harigai, K Sonamoto, Y Tanaka

Miscellaneous
253 Ultra-rare genetic variation in relapsing polychondritis: a whole-exome sequencing study
Y Luo, M A Ferrada, K A Sikora, C Rankin, H D Alessi, D L Kastner, Z Deng, M Zhang, P A Merkel, V B Kraus, A S Allen, P C Grayson

Images in rheumatology
261 Frosted branch angiitis in systemic lupus erythematosus
K Chauban, H Kari, M Tyagi

Letters
263 HLA-DRB1 and HLA-DQA1 associated with immunogenicity to adalimumab therapy in patients with rheumatoid arthritis
C F Yap, N Nair, A de Vries, F C Loeff, A W Morgan, J D Isaacs, A G Wilson, K L Hyrich, A Barton, D Plant

265 IL-17A inhibitor-induced leucocytoclastic vasculitis is responsive to IL-23 blockade in a psoriatic arthritis patient
K C Binod, A Jabbour, P Poudel, K Banki, A Perl

267 IgM antibodies against acetylated proteins as a possible starting point of the anti-modified protein antibody response in rheumatoid arthritis
T J van Wesemael, S Reijn, A Kawakami, A L Donée, G Stoeken, T Maseda, S Kawashiri, T W J Huizinga, M Tanmai, R E M Toes, D van der Woude